Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
Authors
Keywords
Checkpoint inhibitors, Cancer, Solid organ transplantation, Alloimmunity
Journal
Journal for ImmunoTherapy of Cancer
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-04-16
DOI
10.1186/s40425-019-0585-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients
- (2018) Young Kwang Chae et al. CANCER TREATMENT REVIEWS
- Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma
- (2018) James C. Kuo et al. MELANOMA RESEARCH
- Complete Tumor Response to Pembrolizumab and Allograft Preservation in Renal Allograft Recipient on Immunosuppressive Therapy
- (2018) Masood Sadaat et al. Journal of Oncology Practice
- Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients
- (2018) Ouidad Zehou et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Tapering of Immunosuppression and Sustained Treatment With Nivolumab in a Liver Transplant Recipient
- (2017) Enrico N. De Toni et al. GASTROENTEROLOGY
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab
- (2017) Richard Barnett et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma
- (2017) Brian D. Friend et al. PEDIATRIC BLOOD & CANCER
- Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).
- (2017) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- The Bad and the Good News on Cancer Immunotherapy: Implications for Organ Transplant Recipients
- (2016) Umberto Maggiore et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma
- (2016) L. Spain et al. ANNALS OF ONCOLOGY
- Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report
- (2016) Taofeek K. Owonikoko et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- (2016) Christophe Massard et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- Tumor Regression and Allograft Rejection after Administration of Anti–PD-1
- (2016) Evan J. Lipson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Mortality Among Recipients of Solid-Organ Transplantation in Ontario, Canada
- (2016) Sergio A. Acuna et al. JAMA Oncology
- Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
- (2016) Noha Abdel-Wahab et al. PLoS One
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
- (2015) Anne Bertrand et al. BMC Medicine
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center
- (2015) Douglas B. Johnson et al. Cancer Immunology Research
- Disappearance of T Cell-Mediated Rejection Despite Continued Antibody-Mediated Rejection in Late Kidney Transplant Recipients
- (2014) P. F. Halloran et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Malignancy-related mortality following kidney transplantation is common
- (2013) Daniela Farrugia et al. KIDNEY INTERNATIONAL
- Malignancies After Kidney Transplantation: Hong Kong Renal Registry
- (2012) C. Y. Cheung et al. AMERICAN JOURNAL OF TRANSPLANTATION
- PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer
- (2012) John Dulos et al. JOURNAL OF IMMUNOTHERAPY
- Spectrum of Cancer Risk Among US Solid Organ Transplant Recipients
- (2011) Eric A. Engels et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Mortality in Kidney Transplantation
- (2009) B. A. Kiberd et al. AMERICAN JOURNAL OF TRANSPLANTATION
- CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
- (2009) Erika von Euw et al. Journal of Translational Medicine
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started